Kiran Naqvi, MD, UCI - AML

Kiran Naqvi, MD - UCI presents findings on the efficacy and safety of Quizartinib, a FLIT-III inhibitor, in combination therapy for newly diagnosed and relapse refractory AML, showcasing significant improvements in overall survival, response rates, and MRD negativity, with potential implications for frontline treatment strategies.